Management increased full-year 2025 revenue guidance to $80M-100M, excluding ACT Genomics, up from the previous range of $73M-85M, demonstrating confidence in the core business trajectory.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRE:
- Prenetics to divest ACT Genomics to Delta Electronics in $71.78M transaction
- Prenetics Global Limited Appoints New Independent Director to Strengthen Bitcoin Strategy
- Prenetics Global Ltd trading resumes
- Prenetics Global Ltd trading halted, volatility trading pause
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz